Main menu

London Calling 2023: Advancing targeted haplotyping in pharmacogenomics using adaptive sampling


Pharmacogenomics (PGx) encompasses the personalisation of a patient’s drug therapy based on their genomic blueprint. However, current genotyping techniques are still limited in terms of the relevance of the information they provide. Therefore, we applied the recently unrolled adaptive sampling feature on the PromethION device to characterize relevant PGx genes. We targeted a panel of over 1,056 pharmacogenes, including challenging genes such as CYP2D6, from the Pharmacogenomics Knowledge Base. Using the latest R10.4.1 Flow Cells and Native Barcoding Kit V14, we multiplexed reference DNA standards, including the well-characterized GIAB NA12878 sample and performed PromethION sequencing. After superhigh accuracy basecalling, we evaluated variant calling, structural variant detection, and haplotype phasing with respect to the published references and earlier Oxford Nanopore sequencing data from R9.4.1 Flow Cells. Our results confirm the potential added value of the latest Oxford Nanopore sequencing chemistry to inform haplotype-guided pharmacological treatment.

Authors: Koen Deserranno

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

纳米孔技术

订阅 Nanopore 更新 资源库及发表刊物 什么是 Nanopore 社区

关于 Oxford Nanopore

新闻 公司历程 可持续发展 领导团队 媒体资源和联系方式 投资者 合作者 在 Oxford Nanopore 工作 职位空缺 商业信息 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Chinese flag